Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Affronti, ML; Herndon, JE; Patel, MP

Published Date

  • December 2020

Published In

Volume / Issue

  • 28 / 12

Start / End Page

  • 5591 - 5592

PubMed ID

  • 32885313

Electronic International Standard Serial Number (EISSN)

  • 1433-7339

Digital Object Identifier (DOI)

  • 10.1007/s00520-020-05726-0

Language

  • eng

Conference Location

  • Germany